Wells Fargo & Company Biomea Fusion, Inc. Transaction History

Wells Fargo & Company

$433 Billion
Q4 2024

A detailed history of Wells Fargo & Company transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 12,914 shares of BMEA stock, worth $48,169. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,914

Previous 8,515 51.66%

Holding current value

$48,169

Previous $86,000 41.86%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$3.88 - $12.41 $17,068 - $54,591	4,399 Added 51.66%	12,914 $50,000
Q3 2024 Nov 13, 2024	SELL	$4.23 - $10.1 $1,412 - $3,373	-334 Reduced 3.77%	8,515 $86,000
Q2 2024 Aug 13, 2024	BUY	$4.14 - $15.3 $11,902 - $43,987	2,875 Added 48.13%	8,849 $39,000
Q1 2024 May 10, 2024	BUY	$13.92 - $19.5 $11,094 - $15,541	797 Added 15.4%	5,974 $89,000
Q4 2023 Feb 09, 2024	SELL	$8.37 - $19.8 $346,132 - $818,809	-41,354 Reduced 88.87%	5,177 $75,000
Q3 2023 Nov 13, 2023	BUY	$13.44 - $23.02 $200,350 - $343,159	14,907 Added 47.14%	46,531 $640,000
Q2 2023 Aug 15, 2023	BUY	$21.66 - $41.8 $680,513 - $1.31 Million	31,418 Added 15251.46%	31,624 $694,000
Q1 2023 May 12, 2023	BUY	$6.8 - $32.35 $612 - $2,911	90 Added 77.59%	206 $6,000
Q4 2022 Feb 13, 2023	BUY	$6.3 - $11.6 $18 - $34	3 Added 2.65%	116 $0
Q3 2022 Nov 14, 2022	BUY	$9.51 - $13.61 $494 - $707	52 Added 85.25%	113 $1,000
Q2 2022 Aug 12, 2022	SELL	$3.0 - $12.03 $6,087 - $24,408	-2,029 Reduced 97.08%	61 $1,000
Q1 2022 May 16, 2022	SELL	$4.39 - $9.03 $42,978 - $88,403	-9,790 Reduced 82.41%	2,090 $9,000
Q4 2021 Feb 14, 2022	BUY	$7.22 - $12.72 $85,773 - $151,113	11,880 New	11,880 $88,000

Others Institutions Holding BMEA

# of Institutions

118

Shares Held

19.1M

Call Options Held

1.84M

Put Options Held

682K

View Full List

About Biomea Fusion, Inc.

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $109M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

More about BMEA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Biomea Fusion, Inc. Transaction History